The exclusion of CD8+ T cells from the tumor prevents the cell-to-cell contact necessary for TEff cell release of cytolytic effector molecules, including IFN-γ and granzyme B. This immune-specific cell interaction targets tumor and virally infected cells, limiting damage to normal tissue in contrast with the nonspecific killing of rapidly growing cells that occurs with conventional therapies (57–60). The gene discussed is CD8A; the disease is neoplasm.